Cargando…

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data

Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by an increased risk of thrombosis and progression to acute myeloid leukemia. MPN are associated with driver mutations in JAK2, CALR and MPL which a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loscocco, Giuseppe G, Guglielmelli, Paola, Vannucchi, Alessandro M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718985/ https://www.ncbi.nlm.nih.gov/pubmed/33293830 http://dx.doi.org/10.2147/OTT.S287944

Ejemplares similares

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
por: Guglielmelli, Paola, et al.
Publicado: (2010)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2023)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
por: Tenedini, E, et al.
Publicado: (2014)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review
por: Malato, Alessandra, et al.
Publicado: (2020)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms
por: Maze, Dawn, et al.
Publicado: (2022)

The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia
por: Wang, Jingyi, et al.
Publicado: (2016)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
por: Constantinescu, Stefan N., et al.
Publicado: (2021)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
por: Hermouet, Sylvie
Publicado: (2023)

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
por: De Stefano, Valerio, et al.
Publicado: (2018)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis
por: Rosti, Vittorio, et al.
Publicado: (2010)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms
por: Ha, Jung-Sook, et al.
Publicado: (2015)

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
por: Aujla, Amandeep, et al.
Publicado: (2018)

CALR mutations in myeloproliferative neoplasms: An unfolding story
por: Langabeer, Stephen E.
Publicado: (2020)

Prognostication in myeloproliferative neoplasms, including mutational abnormalities
por: Hong, Junshik
Publicado: (2023)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

Genetic basis and molecular profiling in myeloproliferative neoplasms
por: Luque Paz, Damien, et al.
Publicado: (2023)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

A novel assay to detect calreticulin mutations in myeloproliferative neoplasms
por: Rosso, Valentina, et al.
Publicado: (2016)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rlkck26rmi7q78b0dkiuqilg2a